Remicade approved as UC treatment
USA-based pharmaceutical company Schering-Plough says that its biologic Remicade (infliximab) has received a license in the UK for the treatment of severely active ulcerative colitis. Remicade is a chimeric anti-tumor necrosis factor monoclonal antibody, which has been shown to encourage mucosal healing, and is currently licensed for the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis and psoriasis.
The new approval is based on data from two recent studies, ACT 1& 2, in which UC patients who were unresponsive to conventional treatments received Remicade or placebo at a dosage of 5mg/kg per day. The results revealed that those receiving the compound were significantly more likely to produce a clinical response and be in remission at weeks eight and 30 in both trials and week 54 in ACT 1.
The company says that these results are important in light of the recent suggestion that mucosal healing is the strongest predictor of a reduction in the risk of cancer amongst UC patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze